Cybin Inc. (NYSE:CYBN – Get Free Report) shares saw strong trading volume on Monday . 81,682 shares changed hands during trading, a decline of 39% from the previous session’s volume of 134,133 shares.The stock last traded at $9.37 and had previously closed at $9.18.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on CYBN. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Cybin in a report on Friday, August 23rd. Canaccord Genuity Group decreased their price target on shares of Cybin from $114.00 to $96.00 and set a “buy” rating for the company in a research report on Monday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Cybin in a research report on Wednesday, July 31st.
Check Out Our Latest Research Report on Cybin
Cybin Stock Performance
Cybin (NYSE:CYBN – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.01) earnings per share (EPS) for the quarter. On average, equities analysts predict that Cybin Inc. will post -0.08 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Cybin
Several institutional investors have recently modified their holdings of CYBN. RA Capital Management L.P. purchased a new stake in shares of Cybin during the 1st quarter worth $24,041,000. Ikarian Capital LLC purchased a new stake in shares of Cybin during the 1st quarter worth $5,770,000. Rosalind Advisors Inc. lifted its position in shares of Cybin by 38.3% during the 2nd quarter. Rosalind Advisors Inc. now owns 19,300,000 shares of the company’s stock worth $5,230,000 after purchasing an additional 5,340,000 shares during the last quarter. AWM Investment Company Inc. purchased a new stake in shares of Cybin during the 1st quarter worth $930,000. Finally, PEAK6 Investments LLC acquired a new stake in Cybin during the 1st quarter worth $95,000. 17.94% of the stock is owned by hedge funds and other institutional investors.
Cybin Company Profile
Cybin Inc is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc is based in Toronto, Canada.
Read More
- Five stocks we like better than Cybin
- How to Read Stock Charts for Beginners
- The Average 401k Balance by Age Explained
- Using the MarketBeat Dividend Yield Calculator
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Buy P&G Now, Before It Sets A New All-Time High
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.